… 91.0% for exemestane versus 91.2% for anastrozole. They are … , randomized, phase II,
neoadjuvant trial, in which no significance difference in clinical responses was observed between …

… and, to our knowledge, no trial has directly compared the three aromatase inhibitors
anastrozole, exemestane, and letrozole. We investigated the schedule and type of aromatase …

… No significant differences between the 2 drugs in the rates of … of letrozole resulted in higher
clinical and pathological response rates.14 Similarly, 6 months of neoadjuvant exemestane …

… showed no substantial difference between the alpelisib plus letrozole and placebo plus …
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane …

… drugs (anastrozole, letrozole and exemestane) have been … of patients without any differences
between the two AIs used in … A phase II trial conducted by the Hellenic Group of Oncology (…

… that non-steroidal AIs (anastrozole, letrozole) are the agents of … a differential effect for
letrozole and tamoxifen in ILBC and … , but no difference between tamoxifen and anastrozole was …

… In this report, we present the results of a phase II neoadjuvant trial, performed at the …
comparison between the two non-steroidal AIs and direct competitors, anastrozole and letrozole, …

… obtained by neoadjuvant letrozole in patients with early breast cancer in a phase-II design.
… report the pathological and clinical results obtained by four months of neoadjuvant letrozole. …

… Baseline tumor Ki67 index showed no statistical differences between NET and NAC groups
(P … Therefore, in our future randomized controlled phase II or III trial with larger sample size, a …

… mg/month plus either anastrozole or tamoxifen for 24 weeks … plus exemestane significantly
reduced recurrence compared … power to detect a relative difference between treatment arms. …